FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286296421> ?p ?o ?g. }

• W4286296421 endingPage "11546" @default.
• W4286296421 startingPage "11546" @default.
• W4286296421 abstract "11546 Background: Glycosylation is one of the most ubiquitous and functionally important forms of post-translational modification. The role of differential glycosylation in serum proteins has so far been limited by the technical complexity inherent in generating and interpreting this information. InterVenn has built a novel platform that combines liquid chromatography/mass spectrometry with a proprietary artificial-intelligence-based data processing engine, allowing for highly scalable and reproducible interrogation of glycoproteins with site- and glycan-specificity. Methods: Using this platform, we interrogated 519 glycopeptide (GP) biomarkers derived from 70 serum proteins in pre-treatment samples from a cohort of 103 individuals (56 females, 47 males, age ranging from 18 to 84 years) presenting with one of 20 solid cancer types. All patients were treated with durvalumab and tremelimumab immune checkpoint inhibitor (ICI) therapy. Median follow-up for overall survival (OS) was 11.4 months, with 70 events total observed. OS associations were assessed for individual GPs via Cox regression models and leave-one-out-cross-validation (LOOCV) was employed to generate penalized multivariable prediction scores. Notably, 43 patients had a primary diagnosis of bone and soft tissue sarcoma, and stratified analyses were carried out in this population. Results: We identified 154 biomarkers significantly associated with OS in the full dataset after adjusting for multiple comparisons (FDR < 0.05). Of these, 7 were statistically significant at p < 0.01 in the sarcoma-only subset. LOOCV models built in all cancer types resulted in held-out scores that discriminated those likely to exhibit long-term survival post-ICI therapy from those unlikely to benefit (HR = 4.0, p = 4.91E-08, with 4 GPs included in the final model). Furthermore, LOOCV models including only sarcoma patients demonstrated even stronger predictive attributes (HR = 8.22, p = 2.10E-05, employing 2 glycopeptides). All 9 sarcoma patients with extreme glycosylation signatures for prediction of poor survival displayed quick clinical progression with little benefit from ICI therapy. Relative signal strength and comparative analyses demonstrated strong histotype-specificity inherent in the biomarkers employed for sarcoma vs all cancers. Conclusions: Our results indicate that glycoproteomic liquid biopsy holds potential as a predictive biomarker for identifying sarcoma patients who will derive the greatest benefit from ICI therapy." @default.
• W4286296421 created "2022-07-21" @default.
• W4286296421 creator A5009044856 @default.
• W4286296421 creator A5012688551 @default.
• W4286296421 creator A5056579841 @default.
• W4286296421 creator A5057483557 @default.
• W4286296421 creator A5060041987 @default.
• W4286296421 creator A5060182527 @default.
• W4286296421 creator A5073630820 @default.
• W4286296421 creator A5074866369 @default.
• W4286296421 creator A5080428614 @default.
• W4286296421 creator A5081980656 @default.
• W4286296421 creator A5082768519 @default.
• W4286296421 date "2022-06-01" @default.
• W4286296421 modified "2023-09-26" @default.
• W4286296421 title "Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy." @default.
• W4286296421 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.11546" @default.
• W4286296421 hasPublicationYear "2022" @default.
• W4286296421 type Work @default.
• W4286296421 citedByCount "0" @default.
• W4286296421 crossrefType "journal-article" @default.
• W4286296421 hasAuthorship W4286296421A5009044856 @default.
• W4286296421 hasAuthorship W4286296421A5012688551 @default.
• W4286296421 hasAuthorship W4286296421A5056579841 @default.
• W4286296421 hasAuthorship W4286296421A5057483557 @default.
• W4286296421 hasAuthorship W4286296421A5060041987 @default.
• W4286296421 hasAuthorship W4286296421A5060182527 @default.
• W4286296421 hasAuthorship W4286296421A5073630820 @default.
• W4286296421 hasAuthorship W4286296421A5074866369 @default.
• W4286296421 hasAuthorship W4286296421A5080428614 @default.
• W4286296421 hasAuthorship W4286296421A5081980656 @default.
• W4286296421 hasAuthorship W4286296421A5082768519 @default.
• W4286296421 hasConcept C121608353 @default.
• W4286296421 hasConcept C126322002 @default.
• W4286296421 hasConcept C142724271 @default.
• W4286296421 hasConcept C143998085 @default.
• W4286296421 hasConcept C2777701055 @default.
• W4286296421 hasConcept C2778256501 @default.
• W4286296421 hasConcept C2780851360 @default.
• W4286296421 hasConcept C2908647359 @default.
• W4286296421 hasConcept C50382708 @default.
• W4286296421 hasConcept C70721500 @default.
• W4286296421 hasConcept C71924100 @default.
• W4286296421 hasConcept C72563966 @default.
• W4286296421 hasConcept C86803240 @default.
• W4286296421 hasConcept C99454951 @default.
• W4286296421 hasConceptScore W4286296421C121608353 @default.
• W4286296421 hasConceptScore W4286296421C126322002 @default.
• W4286296421 hasConceptScore W4286296421C142724271 @default.
• W4286296421 hasConceptScore W4286296421C143998085 @default.
• W4286296421 hasConceptScore W4286296421C2777701055 @default.
• W4286296421 hasConceptScore W4286296421C2778256501 @default.
• W4286296421 hasConceptScore W4286296421C2780851360 @default.
• W4286296421 hasConceptScore W4286296421C2908647359 @default.
• W4286296421 hasConceptScore W4286296421C50382708 @default.
• W4286296421 hasConceptScore W4286296421C70721500 @default.
• W4286296421 hasConceptScore W4286296421C71924100 @default.
• W4286296421 hasConceptScore W4286296421C72563966 @default.
• W4286296421 hasConceptScore W4286296421C86803240 @default.
• W4286296421 hasConceptScore W4286296421C99454951 @default.
• W4286296421 hasIssue "16_suppl" @default.
• W4286296421 hasLocation W42862964211 @default.
• W4286296421 hasOpenAccess W4286296421 @default.
• W4286296421 hasPrimaryLocation W42862964211 @default.
• W4286296421 hasRelatedWork W1411054225 @default.
• W4286296421 hasRelatedWork W2108026478 @default.
• W4286296421 hasRelatedWork W2596040508 @default.
• W4286296421 hasRelatedWork W3104817578 @default.
• W4286296421 hasRelatedWork W3144899533 @default.
• W4286296421 hasRelatedWork W3193396716 @default.
• W4286296421 hasRelatedWork W4281723870 @default.
• W4286296421 hasRelatedWork W4285038142 @default.
• W4286296421 hasRelatedWork W4289517314 @default.
• W4286296421 hasRelatedWork W4304808194 @default.
• W4286296421 hasVolume "40" @default.
• W4286296421 isParatext "false" @default.
• W4286296421 isRetracted "false" @default.
• W4286296421 workType "article" @default.